Despite reporting lower-than-expected revenue for 2024, Hutchmed (NASDAQ:HCM) traded higher on Wednesday after the Chinese ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Like many pharma stocks, Eli Lilly (NYSE: LLY ... Lilly expects data readouts this year from a phase 3 trial of retatrutide, a weight loss candidate it's suggested may be even more effective ...